Antisense Therapeutics Limited (ATHJF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Antisense Therapeutics Limited (ATHJF) with AI Score 57/100 (Hold). Antisense Therapeutics Limited is an Australian biopharmaceutical company focused on developing antisense oligonucleotide therapies. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Antisense Therapeutics Limited (ATHJF) Healthcare & Pipeline Overview
Antisense Therapeutics Limited is an Australian biopharmaceutical firm specializing in antisense oligonucleotide therapies, particularly ATL1102 for multiple sclerosis and Duchenne Muscular Dystrophy. Currently in Phase II clinical trials, the company targets inflammatory conditions and diseases associated with excessive growth hormone action, operating within the specialty and generic drug manufacturing sector.
Investment Thesis
Antisense Therapeutics Limited presents a high-risk, high-reward investment opportunity within the biopharmaceutical sector. The company's valuation is approximately $20 million, reflecting its early stage and the inherent risks associated with drug development. The primary value driver is the successful progression of ATL1102 through Phase II clinical trials for multiple sclerosis and Duchenne Muscular Dystrophy. Positive trial results could lead to significant increases in the company's valuation. Key growth catalysts include securing partnerships for further development and commercialization of ATL1102 and ATL1103. The company's success hinges on navigating the regulatory approval process and demonstrating clinical efficacy. Potential risks include clinical trial failures, funding challenges, and competition from established pharmaceutical companies. The company's future success depends heavily on the clinical trial outcomes for ATL1102.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.02 billion indicates a micro-cap company with high growth potential but also high risk.
- P/E ratio of -0.57 reflects the company's current lack of profitability, typical for a development-stage biopharmaceutical company.
- Beta of 0.87 suggests the stock is slightly less volatile than the overall market.
- ATL1102 in Phase II clinical trials for multiple sclerosis and Duchenne Muscular Dystrophy represents a key value driver.
- ATL1103 has completed Phase II clinical trials, targeting diseases associated with excessive growth hormone action.
Competitors & Peers
Strengths
- Novel antisense oligonucleotide technology.
- ATL1102 in Phase II clinical trials.
- Experienced management team.
- Focus on unmet medical needs.
Weaknesses
- Limited financial resources.
- Dependence on the success of ATL1102 and ATL1103.
- Early-stage development company.
- High risk of clinical trial failure.
Catalysts
- Upcoming: Results from Phase II clinical trials of ATL1102 for multiple sclerosis expected in late 2026.
- Upcoming: Potential partnerships with larger pharmaceutical companies for further development and commercialization of ATL1102 by 2027.
- Ongoing: Continued research and development of new antisense therapies.
- Ongoing: Advancements in drug delivery technologies could improve the efficacy of ATL1102 and ATL1103.
- Ongoing: Regulatory approvals for ATL1102 and ATL1103 in key markets.
Risks
- Potential: Clinical trial failures for ATL1102 or ATL1103.
- Potential: Regulatory hurdles and delays in obtaining approvals.
- Potential: Competition from established pharmaceutical companies with greater resources.
- Ongoing: Funding challenges and the need to raise additional capital.
- Ongoing: Dependence on the success of a limited number of product candidates.
Growth Opportunities
- Expansion of ATL1102 into new indications: ATL1102, currently in Phase II trials for MS and DMD, has potential applications in other inflammatory conditions such as asthma. Expanding the clinical program to include these indications could significantly increase the drug's market potential. The market for asthma therapeutics is substantial, with a global market size estimated at billions of dollars. Timeline for expansion would depend on the results of ongoing trials and regulatory approvals.
- Partnerships and collaborations: Forming strategic alliances with larger pharmaceutical companies could provide Antisense Therapeutics with the resources and expertise needed to advance its pipeline and commercialize its products. Partnerships could involve licensing agreements, joint ventures, or co-development programs. This would allow Antisense to share the financial burden and accelerate development timelines. Securing a partnership within the next 12-24 months would be a significant catalyst.
- Advancement of ATL1103: ATL1103, which has completed Phase II trials, targets diseases associated with excessive growth hormone action. Further development of this drug could address unmet needs in this area. The market for growth hormone-related therapies is significant, driven by conditions such as acromegaly. The next step would be to initiate Phase III trials, which could take several years to complete.
- Geographic expansion: Currently focused on Australia, Antisense Therapeutics could expand its operations to other regions, such as North America and Europe. This would provide access to larger patient populations and increase the company's market reach. Expansion would require significant investment in clinical trials and regulatory approvals in these regions. This is a longer-term opportunity, potentially 3-5 years out.
- Development of new antisense therapies: Antisense Therapeutics could leverage its expertise in antisense oligonucleotide technology to develop new therapies targeting other diseases. This would diversify the company's pipeline and reduce its reliance on ATL1102 and ATL1103. Identifying new targets and developing new drugs is a long-term process, potentially taking several years.
Opportunities
- Expansion into new indications.
- Partnerships with larger pharmaceutical companies.
- Advancement of ATL1103.
- Geographic expansion.
Threats
- Competition from established pharmaceutical companies.
- Regulatory hurdles.
- Clinical trial failures.
- Funding challenges.
Competitive Advantages
- Patented antisense oligonucleotide technology.
- Clinical data supporting the efficacy of ATL1102 and ATL1103.
- Expertise in antisense drug development.
- First-mover advantage in specific therapeutic areas.
About ATHJF
Antisense Therapeutics Limited, incorporated in 2000 and based in Toorak, Australia, is a biopharmaceutical company dedicated to the research and development of novel antisense pharmaceuticals. The company's primary focus is on developing therapies using antisense oligonucleotides, a class of drugs designed to selectively block the production of specific proteins involved in disease processes. Their lead product candidate, ATL1102, is an antisense inhibitor of CD49d, currently in Phase II clinical trials for the treatment of multiple sclerosis (MS) and Duchenne Muscular Dystrophy (DMD). ATL1102 is also being investigated for potential applications in asthma and other inflammatory conditions. Another key asset in Antisense Therapeutics' pipeline is ATL1103, a second-generation antisense drug engineered to block growth hormone receptor (GHR) expression. By reducing levels of insulin-like growth factor-I (IGF-I) in the blood, ATL1103 aims to treat diseases associated with excessive growth hormone action. ATL1103 has completed Phase II clinical trials. The company operates primarily within Australia, conducting its research and development activities to advance its pipeline of antisense therapeutics. Antisense Therapeutics aims to address unmet medical needs in areas with limited treatment options, focusing on innovative approaches to drug development.
What They Do
- Researches and develops novel antisense pharmaceuticals.
- Focuses on antisense oligonucleotide therapies.
- Develops ATL1102, an antisense inhibitor of CD49d.
- Conducts Phase II clinical trials for ATL1102 in multiple sclerosis and Duchenne Muscular Dystrophy.
- Investigates ATL1102 for asthma and other inflammatory indications.
- Develops ATL1103, a second-generation antisense drug.
- Targets diseases associated with excessive growth hormone action with ATL1103.
Business Model
- Develops and patents novel antisense pharmaceuticals.
- Conducts clinical trials to demonstrate safety and efficacy.
- Seeks regulatory approval from agencies like the FDA or EMA.
- Potentially partners with larger pharmaceutical companies for commercialization.
Industry Context
Antisense Therapeutics operates within the specialty and generic drug manufacturing industry, a segment of the broader healthcare sector. The industry is characterized by intense competition, high research and development costs, and stringent regulatory requirements. The antisense oligonucleotide therapeutics market is a growing niche within the pharmaceutical industry, driven by advancements in drug delivery technologies and a better understanding of disease mechanisms. Key market trends include personalized medicine and targeted therapies. Antisense Therapeutics competes with larger pharmaceutical companies and other biotechnology firms developing similar therapies. The company's success depends on its ability to differentiate its products and secure regulatory approvals.
Key Customers
- Patients suffering from multiple sclerosis.
- Patients suffering from Duchenne Muscular Dystrophy.
- Patients with asthma and other inflammatory conditions.
- Potentially, patients with diseases associated with excessive growth hormone action.
Financials
Chart & Info
Antisense Therapeutics Limited (ATHJF) stock price: Price data unavailable
Latest News
No recent news available for ATHJF.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ATHJF.
Price Targets
Wall Street price target analysis for ATHJF.
MoonshotScore
What does this score mean?
The MoonshotScore rates ATHJF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: James Garner MBA
CEO
James Garner is the CEO of Antisense Therapeutics Limited. He holds an MBA and has extensive experience in the pharmaceutical and biotechnology industries. His background includes roles in business development, strategic planning, and commercialization. Garner has a proven track record of leading and growing companies in the healthcare sector. He brings a wealth of knowledge and expertise to Antisense Therapeutics, guiding the company's strategic direction and overseeing its operations.
Track Record: Under James Garner's leadership, Antisense Therapeutics has advanced its lead product candidate, ATL1102, into Phase II clinical trials for multiple sclerosis and Duchenne Muscular Dystrophy. He has also overseen the development of ATL1103 and secured funding to support the company's research and development activities. Garner has focused on building a strong team and fostering a culture of innovation within the company.
ATHJF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Antisense Therapeutics Limited (ATHJF) may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited or no financial disclosure, making it difficult for investors to assess their financial health and operational performance. Investing in companies on the OTC Other tier carries significantly higher risks compared to those listed on major exchanges like the NYSE or NASDAQ due to the lack of regulatory oversight and transparency.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases the risk of investing in ATHJF.
- Low liquidity can lead to price volatility and difficulty in trading shares.
- The OTC Other tier indicates a higher risk of fraud or mismanagement.
- Lack of regulatory oversight increases the potential for company misconduct.
- The company's financial stability may be uncertain due to limited information.
- Verify the availability and reliability of financial reports.
- Assess the company's management team and their track record.
- Research the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Check for any regulatory actions or legal issues involving the company.
- Confirm the company's contact information and physical address.
- The company has a website and provides some information about its business.
- Antisense Therapeutics is developing pharmaceutical products with potential medical benefits.
- The company has been in operation since 2000.
Antisense Therapeutics Limited Stock: Key Questions Answered
What does Antisense Therapeutics Limited do?
Antisense Therapeutics Limited is an Australian biopharmaceutical company focused on the research and development of novel antisense pharmaceuticals. Their primary focus is on developing therapies using antisense oligonucleotides, a class of drugs designed to selectively block the production of specific proteins involved in disease processes. Their lead product candidate, ATL1102, is in Phase II clinical trials for multiple sclerosis and Duchenne Muscular Dystrophy. The company aims to address unmet medical needs in areas with limited treatment options, focusing on innovative approaches to drug development.
What do analysts say about ATHJF stock?
As of March 16, 2026, there is no readily available analyst coverage for ATHJF due to its OTC listing and small market capitalization. Investment decisions should be based on individual due diligence, considering the inherent risks associated with early-stage biopharmaceutical companies. Key valuation metrics would revolve around the potential market size of ATL1102 and ATL1103, probability of clinical trial success, and potential partnership opportunities. Growth considerations include the successful completion of clinical trials and regulatory approvals.
What are the main risks for ATHJF?
The main risks for Antisense Therapeutics Limited include the potential failure of clinical trials for ATL1102 and ATL1103, which would significantly impact the company's valuation. Regulatory hurdles and delays in obtaining approvals from agencies like the FDA or EMA also pose a risk. Competition from larger pharmaceutical companies with greater resources and established market presence is another significant challenge. Funding challenges and the need to raise additional capital to support ongoing research and development activities represent an ongoing risk. The company's dependence on the success of a limited number of product candidates also increases its vulnerability.
What are the key factors to evaluate for ATHJF?
Antisense Therapeutics Limited (ATHJF) currently holds an AI score of 57/100, indicating moderate score. Key strength: Novel antisense oligonucleotide technology.. Primary risk to monitor: Potential: Clinical trial failures for ATL1102 or ATL1103.. This is not financial advice.
How frequently does ATHJF data refresh on this page?
ATHJF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven ATHJF's recent stock price performance?
Recent price movement in Antisense Therapeutics Limited (ATHJF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Novel antisense oligonucleotide technology.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider ATHJF overvalued or undervalued right now?
Determining whether Antisense Therapeutics Limited (ATHJF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying ATHJF?
Before investing in Antisense Therapeutics Limited (ATHJF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC stocks carry higher risks than exchange-listed stocks.